Eocene Ltd EOCN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Galmed Pharmaceuticals Becomes EoCene, Unveiling New Ticker Symbol "EOCN" to Reflect its New Dawn Platform for GI Innovation
-
Galmed Announces Successful First-in-Human Proof-of-Concept Clinical Study Results for Colospan's Novel Intraoperative Tissue Assessment Technology
-
Galmed Announces First Time Results in Prostate Oncology Studies: Aramchol Demonstrates 3-4 Fold Increase in Cell Death Compared to Enzalutamide (XTANDI®) Alone in Prostate Cancer Models
-
Galmed Announces Breakthrough Development of Dispersible Film Delivery (ODF), Brain Penetrating formulation of its SCD1 inhibitor Aramchol for Parkinson's Disease, Targeting $6 Billion Market
Trading Information
- Previous Close Price
- $3.08
- Day Range
- $2.96–3.27
- 52-Week Range
- $2.33–12.32
- Bid/Ask
- $2.50 / $3.63
- Shares Outstanding
- 1.07M
- Market Cap
- $3.24M
- Volume/Avg
- 8,767 / 30,705
Key Statistics
- Price/Earnings (Normalized)
- 10.89
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Eocene Ltd is a GI-focused medtech and biopharmaceutical company focused on advancing solutions across gastrointestinal disease management, GI oncology and related therapeutic areas. Its wholly owned subsidiary develops medical devices for postoperative colorectal care, including CG-100, an intraluminal bypass device intended to protect colorectal anastomoses and reduce the need for diverting stomas. The company's therapeutic portfolio includes Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule being evaluated in liver disease and oncology indications, including gastrointestinal cancers.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 6
- Website
- https://www.eocn.com
Valuation
|
Metric
|
EOCN
|
|---|---|
Price/Earnings (Normalized) | 10.89 |
Price/Book Value | 0.24 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
EOCN
Financial Strength
|
Metric
|
EOCN
|
|---|---|
Quick Ratio | 4.11 |
Current Ratio | 4.16 |
Interest Coverage | — |
Quick Ratio
EOCN
Profitability
|
Metric
|
EOCN
|
|---|---|
Return on Assets (Normalized) | −43.66% |
Return on Equity (Normalized) | −51.83% |
Return on Invested Capital (Normalized) | −57.23% |
Return on Assets
EOCN
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|<N&^$?Y | LOCK|?j<& | $133B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|f^!wW^$ | LOCK|G!q?# | $83B | |||
| Moderna Inc
MRNA
| LOCK|T?@S@#% | LOCK|?r% | $80B | |||
| argenx SE ADR
ARGX
| LOCK|LYjZM$ | LOCK|K^ | $55B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|p%yd!R% | LOCK|%M | $45B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|!^Pbtr | LOCK|T$%$? | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|s^$^Rvl | LOCK|##DsC | $28B | |||
| Incyte Corp
INCY
| LOCK|@C&Fqv | LOCK|tRq | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|!$<!!%# | LOCK|!^ | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|MY?rgT | LOCK|>& | $14B |
United States